Follow-On Biologics' Bumpy Pathway: Was The CBO Savings Score Too High?

The promise of health care savings from an abundance of biosimilar drugs brought to market under recently passed reforms may go unfulfilled if intellectual property provisions of the law aren't addressed, members of a panel at the BIO annual meeting in Chicago said May 5